Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) Administered in Infants and Toddlers.

Trial Profile

Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) Administered in Infants and Toddlers.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate; Rotavirus W179-9 vaccine; Varicella zoster virus vaccine live
  • Indications Chickenpox; Diphtheria; Haemophilus infections; Measles; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Rubella; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 19 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top